In the penultimate sentence of the Results section of the Abstract, the plus sign should be a plus-or-minus sign. The correct sentence is: One-year survival of trial subjects was 46±15% vs. 0% among historical controls.

In [Table 2](#pone.0133684.t001){ref-type="table"}, spaces are missing before the acronym "PEEP" in the "Pre-Rx O~2~" and "Post-Rx O~2~" columns. Please see the correct [Table 2](#pone.0133684.t001){ref-type="table"} here.

10.1371/journal.pone.0133684.t001

###### Individual Treatment Outcomes.

![](pone.0133684.t001){#pone.0133684.t001g}

  \#   Pre-Rx O~2~                                  Post-Rx O~2~           Comments
  ---- -------------------------------------------- ---------------------- -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  1    F~I~O~2~ 0.7 PEEP 10                         F~I~O~2~ 1.0 PEEP 10   Lung function worsened during treatment. Died on day 11 after recurrent MI.
  2    F~I~O~2~ 0.7 PEEP 10                         50% FM                 Despite improvement, her care was changed to comfort measures only at family request. She was extubated successfully and treated with MS gtts.
  3    15L NC                                       5L NC                  Less dyspnea and ambulating after treatment. Respiratory function remainedimproved post-treatment. Died suddenly on day 76 (cause uncertain but likely cardiac).
  4    10L NC                                       4L NC                  Less dyspnea and ambulating after treatment. Respiratory function remained improved post-treatment for \>365 days.
  5    100% FM Bi-level positive pressure by mask   5L NC                  Less dyspnea and ambulating after treatment. AE-IPF relapsed 3 days later and he required intubation and mechanical ventilation. Repeated TPE x 5, with clinical response and was successfully extubated to 5L NC. He insisted on eating but failed swallow study. He elected CMO status and ate, aspirated, and transferred to SNF on MS gtts. Died on day 32.
  6    60% FM                                       Room Air               Much less dyspnea and ambulating after treatment, and discharged from the hospital. Relapse on day 27 and was treated again with 5x TPE, but did not respond. Died on day 40.
  7    15L NC~oxi~                                  Room Air               Good response but disease recurred 2 d after completion of TPE x 5. Responded again to 6 additional TPE, and discharged to home on room air, where he remained until lung transplantation on day 98.
  8    10L NC                                       3L NC                  Doing well at home on day 237
  9    15L NC~oxi~                                  Room Air               Discharged and returned to work. Awaiting transplant on day 137.
  10   60% FM                                       F~I~O~2~ 0.7 PEEP 10   Did not respond to TPE x 5 and rituximab x 1. Prostate cancer (Stage III) diagnosed by needle biopsy after treatment initiated. Support withdrawn on day 15.
  11   15L NC~oxi~                                  1L                     Discharged to rehabilitation facility. Now at home and doing well on day 96.

Pre and Post are relative to experimental treatment courses (Rx); O~2~ requirements denoted as that necessary to maintain resting arterial oxygen saturations at ≥93%; MI = myocardial infarction; FM = face mask; NC = nasal cannula; NC~oxi~ = nasal cannula with "oxymizer" reservoir; CMO = comfort measures only; MS gtts = morphine sulfate infusion; TPE = therapeutic plasma exchange; SNF = skilled nursing facility.
